AplaGen GmbH and Lonza Ltd have signed a licensing agreement for AplaGen's CFPS-Technology

12-May-2004

Lonza Ltd, Switzerland, and AplaGen, Germany closed a combined cooperation and licensing agreement for AplaGen's "CFPS"-Technology (correctly folded peptide synthesis), a new and emerging method for the synthesis of longer mer peptides and proteins. Today peptides and proteins are required by the worldwide market as rather longer-chained products. Especially in the solid phase peptide synthesis, folding and refolding of the candidates gain higher importance. Additionally the young CFPS-technology provides certain advantages during rapid purification on large scale.

Peptides and Proteins are mainly used as therapeutics in the pharmaceutical area. The indications for these classes are broad and are ranging from diabetes, HIV, cancer; infectious diseases; endocrinology, cardiovascular, etc.

Dirk Oehlers, Head of Sales and Business Development TIDES - Lonza Ltd, Dr. Franzpeter Bracht and Prof. Hans-Georg Frank, Managing Directors of AplaGen, agree: "CFPS is a very interesting and very promising technology with a large potential as the today's and especially the future market is requiring this special technology. Lonza is the right partner for large scale industrial manufacture to cGMP standards."

https://www.bionity.com/en/news/37589/aplagen-gmbh-and-lonza-ltd-have-signed-a-licensing-agreement-for-aplagen-s-cfps-technology.html